- Home
- INAB vs GNPX Comparison
INAB vs GNPX Comparison
Compare INAB & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INAB
- GNPX
- Stock Information
- Founded
- INAB 2016
- GNPX 2009
- Country
- INAB United States
- GNPX United States
- Employees
- INAB N/A
- GNPX N/A
- Industry
- INAB Biotechnology: Pharmaceutical Preparations
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- INAB Health Care
- GNPX Health Care
- Exchange
- INAB Nasdaq
- GNPX Nasdaq
- Market Cap
- INAB 10.6M
- GNPX 10.8M
- IPO Year
- INAB 2021
- GNPX 2018
- Fundamental
- Price
- INAB $1.63
- GNPX $4.00
- Analyst Decision
- INAB Strong Buy
- GNPX
- Analyst Count
- INAB 2
- GNPX 0
- Target Price
- INAB $108.00
- GNPX N/A
- AVG Volume (30 Days)
- INAB 72.9K
- GNPX 779.2K
- Earning Date
- INAB 11-06-2025
- GNPX 11-14-2025
- Dividend Yield
- INAB N/A
- GNPX N/A
- EPS Growth
- INAB N/A
- GNPX N/A
- EPS
- INAB N/A
- GNPX N/A
- Revenue
- INAB N/A
- GNPX N/A
- Revenue This Year
- INAB N/A
- GNPX N/A
- Revenue Next Year
- INAB N/A
- GNPX N/A
- P/E Ratio
- INAB N/A
- GNPX N/A
- Revenue Growth
- INAB N/A
- GNPX N/A
- 52 Week Low
- INAB $1.53
- GNPX $3.90
- 52 Week High
- INAB $12.53
- GNPX $78.00
- Technical
- Relative Strength Index (RSI)
- INAB 32.35
- GNPX 48.41
- Support Level
- INAB $1.53
- GNPX $7.71
- Resistance Level
- INAB $1.77
- GNPX $5.00
- Average True Range (ATR)
- INAB 0.17
- GNPX 0.74
- MACD
- INAB -0.02
- GNPX -0.41
- Stochastic Oscillator
- INAB 12.28
- GNPX 3.04
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.